CA2290963C - S-omeprazole magnesium trihydrate - Google Patents
S-omeprazole magnesium trihydrate Download PDFInfo
- Publication number
- CA2290963C CA2290963C CA002290963A CA2290963A CA2290963C CA 2290963 C CA2290963 C CA 2290963C CA 002290963 A CA002290963 A CA 002290963A CA 2290963 A CA2290963 A CA 2290963A CA 2290963 C CA2290963 C CA 2290963C
- Authority
- CA
- Canada
- Prior art keywords
- omeprazole
- magnesium salt
- trihydrate
- salt
- magnesium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Abstract
The present invention relates to a novel form of the (-)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H- benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.
Description
23940-1126(S) S-OMEPRAZOLE MAGNESIUM TRIHYDRATE
Field of the Invention The present invention relates to a novel form of the (-)-enantiomer of ~-methoxy-2-[[(4-s methoxy-3,5-dimethyl-2-pyridinyl)-methyljsulfinyl]-1H-benzimidazole, i.e. S-omeprazole.
More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to intermediates used in the process, and io their preparation.
Background of the invention and prior art The compound ~-methoxy-2-[j(4-methoxy-3,5-dimethyl-2-pyridinyl)methyI]sulfinyl]-IH-is benzimidazole, having the generic name omeprazole, and therapeutically acceptable salts thereof, are described in EP 5129. The specific alkaline salts of omeprazole are disclosed in EP 124 495. Omeprazole is a proton pump inhibitor, i.e. effective in inhibiting gastric acid secretion, and is useful as an antiulcer agent. In a more general sense, omeprazole may be used for prevention-and treatment of gastric-acid related diseases in mammals and ~o especially in man.
Omeprazole is a sulfoxide and a chiral compound, wherein the sulfur atom being the stereogenic center. Thus, omeprazole is a racemic mixture of its two single enantiomers, the R and S-enantiomer of omeprazole, herein referred to as R-omeprazole and S-~s omeprazole. The absolute configurations of the enantiomers of omeprazole have been determined by an X-ray study of an N-alkylated derivative of the (+)-enantiomer in non-salt form. The (+}-enantiomer of the non-salt form and the (-)-enantiomer of the non-salt form were found to have R and S configuration, respectively, and the (+)-enantiomer of the magnesium salt and the (-)-enantiomer of the magnesium salt were also found to have R
Field of the Invention The present invention relates to a novel form of the (-)-enantiomer of ~-methoxy-2-[[(4-s methoxy-3,5-dimethyl-2-pyridinyl)-methyljsulfinyl]-1H-benzimidazole, i.e. S-omeprazole.
More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to intermediates used in the process, and io their preparation.
Background of the invention and prior art The compound ~-methoxy-2-[j(4-methoxy-3,5-dimethyl-2-pyridinyl)methyI]sulfinyl]-IH-is benzimidazole, having the generic name omeprazole, and therapeutically acceptable salts thereof, are described in EP 5129. The specific alkaline salts of omeprazole are disclosed in EP 124 495. Omeprazole is a proton pump inhibitor, i.e. effective in inhibiting gastric acid secretion, and is useful as an antiulcer agent. In a more general sense, omeprazole may be used for prevention-and treatment of gastric-acid related diseases in mammals and ~o especially in man.
Omeprazole is a sulfoxide and a chiral compound, wherein the sulfur atom being the stereogenic center. Thus, omeprazole is a racemic mixture of its two single enantiomers, the R and S-enantiomer of omeprazole, herein referred to as R-omeprazole and S-~s omeprazole. The absolute configurations of the enantiomers of omeprazole have been determined by an X-ray study of an N-alkylated derivative of the (+)-enantiomer in non-salt form. The (+}-enantiomer of the non-salt form and the (-)-enantiomer of the non-salt form were found to have R and S configuration, respectively, and the (+)-enantiomer of the magnesium salt and the (-)-enantiomer of the magnesium salt were also found to have R
and S configuration, respectively. The conditions for the optical rotation measurement for each of these enantiomers are described in WO 94/27988.
Certain salts of single enantiomers of omeprazole and their preparation are disclosed in WO 94/27988. These compounds have improved pharmacokinetic and metabolic properties which will give an improved therapeutic profile such as a lower degree of interindividual variation.
WO 96/02535 discloses a process for the preparation of the single enantiomers of io omeprazole and salts thereof, and WO 96/01623 discloses a suitable tabIeted dosage forms of for instance magnesium salts of R- and S-omeprazole.
Brief description of the drawings is Figure i shows a X-ray powder diffractogram of the magnesium salt ofS-omeprazole trihydrate prepared according to the present invention.
Figure 2 shows a X-ray powder diffractogram of the potassium salt of S-omeprazole prepared and used in the present application (See examples 2 and 3) Figure 3 shows a X-ray powder diffractogram of a magnesium salt ofS-omeprazole zo dehydrate prepared and used in the present application (See example 5) Figure 4 shows a X-ray powder diffractogram of a magnesium salt of S-omeprazole dehydrate which is a polymorph of the dehydrate shown in Figure 3 (See Example 6). This magnesium salt of S-omeprazole dehydrate has been prepared and can be used in the preparation of the magnesium salt of S-omeprazole trihydrate according to the present ~s invention.
Figure 5 shows X-ray powder diffractogram of the magnesium salt ofS-omeprazole prepared according to example A in WO 96/01623 .
23940-1126(S) Description of the Invenrion It has surprisingly been found that the magnesium salt of S-omeprazole occurs in a number of structurally different forms. The present invention provides a substantially pure magnesium salt of S-omeprazole trihydrate, hereinafter referred to as the compound of the invention. This trihydrate can be obtained as a well defined compound.
The present invention also provides a process to obtain and a method of differentiating the magnesium salt of S-omeprazole trihydrate from other forms of magnesium salts of S-omeprazole.
~o The compound of the invention is advantageous because it is .more stable than the corresponding magnesium salt compounds in prior art and is therefore easier to handle and store. The compound of the invention is also easier to characterize because it exists in a well defined state. Additionally, the compound of the invention is easier to synthesize in a ~s reproducible manner and thereby easier to handle in a full scale production.
The magnesium salt of S-omeprazole trihydrate obtained according to the present invention is substantially free from magnesium salts of R-omeprazole. The magnesium salt of S-omeprazole trihydrate obtained according to the present invention is also substantially free xo from other forms of magnesium salts of S-omeprazole, such as the corresponding magnesium salt compounds described in prior art, and dihydrates used in the preparation of the trihydrate compound according to the present invention.
The compound of the invention is characterized by the positions and intensities of the ~s major peaks in the X-ray powder diffractogram , but may also be characterized by conventional FT-IR spectroscopy. These characteristics are not exhibited by any other form of magnesium salt of S-omeprazole and accordingly, the magnesium salt of S-omeprazole trihydrate is easily distinguishable from any other crystal form of the magnesium salt ofS-omeprazole disclosed in prior art. The compound of the invention is characterized by being 23940-1126(S) highly crystalline, i.e. having a higher crystallinity than any other form of magnesium salt of S-omeprazole disclosed in the prior art. With the expression "any other form" is meant anhydrates, hydrates, solvates, and polymorphs or amorphous forms thereof disclosed in the prior art. Examples of any other forms of magnesium salt of S-omeprazole includes, but are not limited to, anhydrates, monohydrates, dihydrates, sesquihydrates, trihydrates, alcoholates, such as methanolates and ethanolates, and polymorphs or amorphous forms thereof.
The compound of the invention may also be characterized by its unit cell.
~o In a further aspect, the present invention provides processes for the preparation of the magnesium salt of S-omeprazole trihydrate which comprises;
a) treating a magnesium salt of S-omeprazole of any form, for example prepared according ~s to procedures known in the art such as Example A in WO 96/01623, with water at a suitable temperature for a suitable time. By a suitable temperature is meant a temperature which induces the transformation of starting material to product without decomposing any of these compounds. Examples of such suitable temperatures include, but are not limited to, room temperature and above. By a suitable ~o time is meant a time that results in high conversion of the starting material into product without causing any decomposition of either compounds, i.e. results in a good yield. This suitable time will vary depending on the temperature used in a way well known to people in the art. The higher the temperature, the shorter time is needed to give the desired conversion. The amount of water is not crucial and will depend on the process conditions ~s used. The magnesium salt of S-omeprazole trihydrate is thereafter separated from the aqueous slurry, for example by filtration or centrifugation and thereafter dried to constant weight; or b) oxidizing 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-~o benzimidazole, with an oxidizing agent and a chiral titanium complex, optionally in the presence of a base. The oxidation is carried out in an organic solvent, for example toluene or dichloromethane.
The crude product is converted to the corresponding potassium salt by treatment with a potassium source, such as methanolic potassium hydroxide or methanolic potassium methylate, followed by isolation of the formed salt.
The resulting potassium salt of S-omeprazole is thereafter converted to the corresponding magnesium salt by treatment with a magnesium source, such as magnesium sulfate in a lower alcohol, such as methanol. The solution is optionally filtered and the precipitation is ~o initialized by addition of a non-solvent such as acetone. The product is filtered off and optionally washed with water and further processed as is described in a) above.
Alternatively, the potassium salt may be treated with a magnesium source, such as magnesium sulfate in water, and isolation of the magnesium salt of S-omeprazole trihydrate, or any other conventional technique for transforming a potassium salt to the ~s corresponding magnesium salt can be used and is within the scope of the present invention.
Yet a further aspect of the present invention is to provide a suitable intermediate used in the preparation of the compound of the invention, as well as a process for its preparation.
The potassium salt of S-omeprazole is found to be such a suitable intermediate. The 2o potassium salt of S-omeprazole may also be used as an active component of a pharmaceutical formulation to be used in the treatment of gastrointestinal diseases.
The compound of the invention, i.e. the magnesium salt of S-omeprazole trihydrate , prepared according to the present invention may be analyzed by XRPD, a technique which zs is known per se.
The amount of water in the magnesium salt of S-omeprazole trihydrate is determined by thermogravimetric analysis, a technique which is known per se.
The compound of the invention is effective as a gastric acid secretion inhibitor, and is useful as an antiulcer agent. In a more general sense, it can be used for prevention and treatment of gastric-acid related conditions in mammals and especially in man, including e. g. reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, s it may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, and in patients with gastrinomas. The compound of the invention may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre- and postoperatively to ~o prevent aspiration of gastric acid and to prevent and treat stress ulceration. Further, the compound of the invention may be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections and diseases related to these. The compound of the invention may also be used for treatment of inflammatory conditions in mammals, including man.
as Any suitable route of administration may be employed for providing the patient with an effective dosage of the magnesium salt of S-omeprazole trihydrate, according to the invention. For example, peroral or parental formulations and the like may be employed.
Dosage forms include capsules, tablets, dispersions, suspensions and the like.
zo It is further provided a pharmaceutical composition comprising the magnesium salt of S-omeprazole trihydrate according to the invention, as active ingredient, in association with a pharmaceutically acceptable carrier, diluent or excipient and optionally other therapeutic ingredients. Compositions comprising other therapeutic ingredients are especially of 2s interest in the treatment of Helicobacter infections. The invention also provides the use of the magnesium salt of S-omeprazole trihydrate of the invention in the manufacture of a medicament for use in the treatment of a gastric-acid related condition and a method of treating a gastric-acid related condition which method comprises administering to a subject suffering from said condition a therapeutically effective amount of the magnesium salt of 3o S-omeprazole trihydrate according to the invention.
23940-1126(S) The compositions of the invention include compositions suitable for peroral or parental administration. The most preferred route is the oral route. The compositions may be conveniently presented in unit dosage forms, and prepared by any methods known in the art of pharmacy.
In the practice of the invention, the most suitable route of administration as well as the magnitude of a therapeutic dose of the magnesium salt of S-omeprazole trihydrate according to the invention in any given case will depend on the nature and severity of the ~o disease to be treated. The dose, and dose frequency, may also vary according to the age, body weight, and response of the individual patient. Special requirements may be needed for patients having Zollinger-Ellison syndrome, such as a need for higher doses than the average patient. Children and patients with liver diseases generally will benefit from doses that are somewhat lower than the average. Thus, in some conditions it may be necessary to ~s use doses outside the ranges stated below, for example long term treatments may request lower dosage. Such higher and lower doses are within the scope of the present invention.
Such daily doses may vary between 5 mg to 300 mg.
In general, a suitable oral dosage form of the compound of the invention may cover a dose ~o range from 5 mg to 300 mg total daily dose, administered in one single dose or equally divided doses. A preferred dosage range is from 10 mg to 80 mg.
The compound of the invention may be combined as the active component in intimate admixture with a pharmaceutical carrier according to conventional techniques, such as the 's oral formulations described in WO 96/01623 and EP 247 983.
Combination preparations comprising the magnesium salt of S-omeprazole trihydrate and other active ingredients may also be used. Examples of such active ingredients include, but 23940-1126(S) 8.
are not limited to anti-bacterial compounds, non-steroidal anti-inflammatory agents, antacid agents, alginates and prokinetic agents.
In a further aspect, the invention provides a commercial package comprising the magnesium salt of S-omeprazole trihydrate of the invention or a pharmaceutical composition thereof and associated therewith instructions for the use thereof in the treatment of a gastric acid related condition in a subject suffering from the condition.
The examples which follow will further illustrate the preparation of the compound of the invention, according to different process routes and including new intermediates. These examples are not intended to limit the scope of the invention as defined hereinabove or as claimed below.
Examples ~s ao Example I
S-S-methoxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)-methylJsulfzrcylJ 1H-benzimidazole magnesium salt trihydrate Water ( 157 kg) was added to the wet crystals of the magnesium salt of S-omeprazole, prepared according to Example 4, below. The mixture was heated to 38°C
with stirring and left for 3 hours. The crystals were filtered off and dried in vacuo. Yield:
31.6 kg '-s X-ray powder diffraction analysis was performed on a sample of the crystals prepared above according to standard methods, which can be found in e.g. Kitaigorodsky, A. I.
( 1973), Molecular Crystals and Molecules, Academic Press, New York; Bunn, C.
W.
( 1948), Chemical Crystallography, Clarendon Press, London; or Klug, H.P. &
Alexander, L. E. ( 1974), X-Ray Diffraction Procedures, John Wiley and Sons, New York.
The analysis gave the diffractogram depicted in Figure 1. The main peaks, with positions and relative intensities, have been extracted from the diffractogram in Figure 1 and is given below in table 1. The relative intensities are less reliable and instead of numerical values the following definitions are used.
% Relative Intensity Definition 25-100 vs (very strong) 10-25 s (strong) 3-10 m (medium) s 1-3 w (weak) < 1 vw (very weak) Some additional very weak peaks found in the diffractogram have been omitted from table 1.
~o Table 1. Positions and intensities of the major peaks in the XRP-diffractogram of the magnesium salt of S-omeprazole trihydrate.
d-value Relative l ~ i L
i 2.67 ~ m 2.79 ~ m 3.27 m i 3.52 ~ s 3.82 ~ s i 3.96 ~ vs 4.14 w m i 5.2 ~ m i 5.6 ~ m i 6.7 i vs i 6.9 I s t 8.3 ; w 16.6 vs Example 2 S-5-methaxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)methylJsulfinylJ-IH-benzimidazole potassium salt s A solution of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-benzimidazole (15.4 g, 46.8 mmol) in toluene {70 ml) was heated to 50°C
and water (0.05 ml, 2,8 mmol) and D-(-)-diethyl tartrate (2.02 g, 9.82 mlnol) were added. The reaction mixture was stirred for 20 minutes. Titanium(IV)isopropoxide ( 1.34 g, 4.68 mmol) was io added and the reaction mixture was stirred for 45 minutes. The mixture was cooled to 30°C
and diisopropylethylamine (0.91 g, 7.01 mmol) was added followed by cumene hydroperoxide (9.52 g, 51.89 mmol). The resultant mixture was stirred at 30°C for 3 hours.
Methanol (40 mI) was added followed by potassium hydroxide (3.05 g, 46.8 mmol) in methanol (30 ml). Seed crystals were added and the reaction mixture was stirred at 35°C
is overnight. The precipitated product was filtered off, washed with methanol and toluene and dried in vacuo. Yield: 9.74 g (54%).
Example 3 2o S-5-methoxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)-methylJsulfxnylJ-IH-benzimidazole potassium salt Water (157.6 p.l) was added to a solution of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyi)methyl]thio]-1H-benzimidazole in toluene (370 ml; 211.5 g/1) with a water zs content of 0.031 % (w/w), followed by addition of D-(-)-diethyl tartrate (8.55 ml). The solution was heated to 50°C and stirred at this temperature for 20 minutes.
Titanium(IV)isopropoxide (7.15 ml) was added and reaction was left at 50°C for 45 minutes. The temperature was lowered to 30°C and diisopropylethyiamine (6.2 ml) was added. Cumene hydroperoxide was added at an appropriate speed to maintain the so temperature from 28°C to 34°C. The temperature was raised to 35°C after 2 hours and potassium methoxide (24.55 g) in methanol (222 ml) was added. The mixture was filtered after 14 hours and the crystals were washed with methanolaoluene (240 ml; l:l) and methanol (120 ml) and dried. Yield: 79 g (74%), ee > 99.9%.
a = +28.7 c = 1 %, water ; Assa : 89% is S-5-methox -2 4-methox -3,5-L JD2~ ° { ) Y Y -LE{ Y
s dimethyl-2-pyridinyl)-methyl]sulfinyl]-IH-benzimidazole potassium salt (l l%
is methanol).
1H-NMR (200 MHz, DMSO-db, 8 ppm): 2.23 (s, 3H), 2.24 (s, 3H), 3.71 (s, 3H), 3.75 {s, 3H), 4.40 (d, 1H), 4.78 (d, IH), 6.58 (dd, 1H), 7.00 (d, 1H), 7.35 (d, 1H), 8.25 {s, 1H).
~o The products from Examples 2 and 3 were analysed using X-ray powder diffraction as described in Example 1 and gave the diffractogram depicted in Figure 2 and given below in Table 2. Some additional very weak peaks found in the diffractogram have been omitted from Table 2.
is Table 2. Positions and intensities of the major peaks in the XRP-diffractograrn of the potassium salt of S-omeprazole.
d-value/A Relatived-value/ Relative intensit(~) intensit 13.6 vs 3.52 m 10.6 vw 3.42 w 7.8 m I 3.38 w 6.8 m 3.34 m 6.5 m 3.28 w 6.2 w 3.20 m 6.1 m ~ 3.12 w 5.8 s 3.06 w 5.4 m I 3.03 w 5.3 w 2.97 w oc 1 = 1.54060 A
5.2 w 2.93 vw 5.0 vw 2.89 w 4.75 m 2.85 m 4.71 w 2.76 w 4.52 w 2.71 vw 4.42 w ~ 2.66 . vw 4.32 w 2.58 w 4.27 m ~ 2.57 w 3.98 vw I 2.56 w 3.92 w 2.52 vw 3.89 w ~ 2.47 vw 3.87 w 2.45 vw 3.81 w 2.43 vw 3.74 m 1 2.40 vw 3.60 m 1 2.38 vw 3.55 ~ m I 2.31 vw Example 4 S-S-methoxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)-methylJsulfinylJ-IH-benzimidazole magnesium salt s Methanol ( 148 kg) was added to S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-IH-benzimidazole potassium salt (71 kg, methanol content =
13%).
MgS04 x 7 H20 (40 kg) was added to the mixture while stirring. After 70 minutes the mixture was filtered and the filtrate was washed with methanol (46 kg). The solution was io concentrated to a volume of 100 liter, acetone (253 kg) was added and the resulting mixture was left for 4 hours. The precipitated product was filtered off, washed with acetone and water. The wet crystals were immediately used as is described in Example 1.
Example 5 ~s S-5-methoxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)-methylJsulftnylJ-IH
benzimidazole magnesium salt dehydrate 5.0 g of the moist product from Example 4 with an approximate dry content of 74%, was 2o dried in vacuum at 35 °C over night to yield 3.58 g (2.68 mmol) of S-5-methoxy-2-[[(4-methoxy-3,S-dimethyi-2-pyridinyl)-methylJsulflnyl]-1H-benzimidazole magnesium salt dehydrate, named Form B.
The product was analyzed using X-ray powder diffraction as described in Example l, and 2s the analyze gave the diffractogram depicted in Figure 3 and given below in Table 3. Some additional peaks with low intensities found in the diffractogram have been omitted from Table 3.
Table 3. Positions and intensities of the major peaks in the XRP-diffractogram of the magnesium salt of S-omeprazole dehydrate, Form B.
d-value / A Relative Intensit 4.19 m 4.45 m 4.68 m 4.79 s 4.91 s 4.98 s 5.1 m 5.4 s 5.5 m 5.6 m 5.8 m 6.3 m 6.7 s 7.9 m 8.1 s i 1.0 m 11.8 m 14.9 vs Convertion of magnesium salt of S-omeprazole dehydrate to trihydrate This material was subsequently processed to S-S-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt trihydrate according to the procedure described for the moist substance in Example 1.
WO 98/54171 PCTlSE98/00974 Example 6 S-5-methoxy-2-~((4-methoxy-3,5-dimethyl-2 pyridinyl)-methylJsul~nylJ-IH-benzimidazole magnesium salt dehydrate A methanolic solution of S-S-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinylJ-IH-benzimidazole magnesium salt was prepared as is described in Example 4. Such a solution of S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulflnyl]-IH-benzimidazole magnesium salt (1.86g) in 5 mI methanol was io concentrated by evaporation until I.58 ml methanol remained. Then, a mixture of 1.6 ml water and 6.32 rnl aceton was added. The solution was allowed to crystallize during 26 h at room temperature. The resulting crystals were filtered off and dried at 40 °C under reduced pressure giving 1.17 g of S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfmylJ-1H-benzimidazole magnesium salt dehydrate, named form A.
is The product was analyzed using X-ray powder diffration as described in Example 1 and gave the diffractogram depicted in Figure 4 and given below in Table 4. Some additional peaks with low intensities found in the diffractogram have been omitted from Table 4.
zo Table 4. Positions and intensities of the major peaks in the XRP-diffractogram of the magnesium salt of S-omeprazole dehydrate, Form A.
d-value / A Relative Intensit 3.04 s 3.14 s 3.18 m 4.05 s 4.19 s 4.32 m 4.54 s 4.69 vs 5.2 s 5.3 s 5.8 s 6.2 vs 6.6 s 15.5 vs Example 7 S-S-methoxy-2-jj(4-methoxy-3,S-dimethyl-2 pyridinyl)-methylJsul~nylJ-1H-s benzimidazole magnesium salt trihydrate 22,0 g (29,1 mmol) of S-5-methoxy-2-[[{4-methoxy-3,5-dimethyl-2-pyridinyl) methyl]sulfinyl]-1H-benzimidazole potassium salt was dissolved in 40 mL of water. The solution was seeded with 0,11 g (0,1 mmol) S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-~o pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt trihydrate. 22 mL (69,6 mmol) of MgS04 (aq) was added under a 3 h period. The slurry was filtered off and the precipitate was elutriated in water for approximately 30 minutes and the crystals were filtered off and dried (35 °C, vacuum).
Yield: 9,15 g ( 11,6 mmol; 80%). The substance had a purity (HPLC):99,8 area%, Mg content: 3,40 % (w/w) and ee: 99,8%.
The product was analyzed using X-ray powder diffraction and the result complies with s Figure 1 and Table 1.
Reference Example A
S-5-methoxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)-methyl)sulJinylJ-IH-~o benzimidazole magnesium salt (The method used is in accordance with the method described in Example A in WO
96/01623) ~s Magnesium (0.1 lg, 4.5 mmol) was dissolved and reacted with methanol (SO
ml) at 40°C
with a catalytic amount of methylene chloride. The reaction was run under nitrogen and was finished after five hours. At room temperature a mixture of the two enantiomers [90%(-)-isomer and 10%(+)-isomer] of 5-methoxy-2-([(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulflnyl]-1H-benzimidazole (2.84 g, 8.2 mmoi) was added to the zo magnesium methoxide solution. The mixture was stirred for 12 hours whereupon a small amount of water (0.1 ml) was added in order to precipitate inorganic magnesium salts.
After 30 minutes stirring, these inorganic salts were filtered off and the solution was concentrated on a rotavapor. The residue was now a concentrated methanolic solution of the enantiomeric mixture (i.e. the title compound contaminated with the (+)-isomer), with zs an optical purity (enantiomeric excess, e-e.) of 80%. This mixture was diluted with acetone ( 100 ml) and after stirring at room temperature for 15 minutes, a white precipitate was obtained. Additional stirring for 15 minutes and thereafter filtration afforded 1.3 .g (50%) of the title compound as white crystals. Chiral analyses of the crystals and mother liquor were performed by chromatography on an analytical chiral column. The optical purity of the so crystals and mother liquor was found to be 98.4 e-e. and 64.4% e-e., respectively. Thus, the optical purity e.e.) has been enhanced from 80% to 98.4% simply by crystallizing the Mg-salt from a mixture of acetone and methanol. The product was crystalline as shown by powder X-ray diffraction and the magnesium content was 3.44% as shown by atomic absorption spectroscopy. [oc]D20 _131.5° (c=0.5%, methanol).
The product was analyzed using X-ray powder diffraction as described in Example 1 and gave the diffractogram depicted in Figure 5 and given below in Table 5. Some additional very weak peaks found in the diffractograms have been omitted from Table 5.
Table 5. Positions and intensities of the major peaks in the XRP-diffractogram shown in Figure 5.
i d-value Relative Intensi l ~ ;
E
2.90 ~ s 3.41 j s 3.90 ~ s 4.i3 ~ s 4.79 ' vs 5.00 i vs 5.4 ~ vs 5.7 ~ s 6.3 s 6.8 s 7.8 s 8.4 ~ vs I0.8 $ s 12.2 s 15.1 vs
Certain salts of single enantiomers of omeprazole and their preparation are disclosed in WO 94/27988. These compounds have improved pharmacokinetic and metabolic properties which will give an improved therapeutic profile such as a lower degree of interindividual variation.
WO 96/02535 discloses a process for the preparation of the single enantiomers of io omeprazole and salts thereof, and WO 96/01623 discloses a suitable tabIeted dosage forms of for instance magnesium salts of R- and S-omeprazole.
Brief description of the drawings is Figure i shows a X-ray powder diffractogram of the magnesium salt ofS-omeprazole trihydrate prepared according to the present invention.
Figure 2 shows a X-ray powder diffractogram of the potassium salt of S-omeprazole prepared and used in the present application (See examples 2 and 3) Figure 3 shows a X-ray powder diffractogram of a magnesium salt ofS-omeprazole zo dehydrate prepared and used in the present application (See example 5) Figure 4 shows a X-ray powder diffractogram of a magnesium salt of S-omeprazole dehydrate which is a polymorph of the dehydrate shown in Figure 3 (See Example 6). This magnesium salt of S-omeprazole dehydrate has been prepared and can be used in the preparation of the magnesium salt of S-omeprazole trihydrate according to the present ~s invention.
Figure 5 shows X-ray powder diffractogram of the magnesium salt ofS-omeprazole prepared according to example A in WO 96/01623 .
23940-1126(S) Description of the Invenrion It has surprisingly been found that the magnesium salt of S-omeprazole occurs in a number of structurally different forms. The present invention provides a substantially pure magnesium salt of S-omeprazole trihydrate, hereinafter referred to as the compound of the invention. This trihydrate can be obtained as a well defined compound.
The present invention also provides a process to obtain and a method of differentiating the magnesium salt of S-omeprazole trihydrate from other forms of magnesium salts of S-omeprazole.
~o The compound of the invention is advantageous because it is .more stable than the corresponding magnesium salt compounds in prior art and is therefore easier to handle and store. The compound of the invention is also easier to characterize because it exists in a well defined state. Additionally, the compound of the invention is easier to synthesize in a ~s reproducible manner and thereby easier to handle in a full scale production.
The magnesium salt of S-omeprazole trihydrate obtained according to the present invention is substantially free from magnesium salts of R-omeprazole. The magnesium salt of S-omeprazole trihydrate obtained according to the present invention is also substantially free xo from other forms of magnesium salts of S-omeprazole, such as the corresponding magnesium salt compounds described in prior art, and dihydrates used in the preparation of the trihydrate compound according to the present invention.
The compound of the invention is characterized by the positions and intensities of the ~s major peaks in the X-ray powder diffractogram , but may also be characterized by conventional FT-IR spectroscopy. These characteristics are not exhibited by any other form of magnesium salt of S-omeprazole and accordingly, the magnesium salt of S-omeprazole trihydrate is easily distinguishable from any other crystal form of the magnesium salt ofS-omeprazole disclosed in prior art. The compound of the invention is characterized by being 23940-1126(S) highly crystalline, i.e. having a higher crystallinity than any other form of magnesium salt of S-omeprazole disclosed in the prior art. With the expression "any other form" is meant anhydrates, hydrates, solvates, and polymorphs or amorphous forms thereof disclosed in the prior art. Examples of any other forms of magnesium salt of S-omeprazole includes, but are not limited to, anhydrates, monohydrates, dihydrates, sesquihydrates, trihydrates, alcoholates, such as methanolates and ethanolates, and polymorphs or amorphous forms thereof.
The compound of the invention may also be characterized by its unit cell.
~o In a further aspect, the present invention provides processes for the preparation of the magnesium salt of S-omeprazole trihydrate which comprises;
a) treating a magnesium salt of S-omeprazole of any form, for example prepared according ~s to procedures known in the art such as Example A in WO 96/01623, with water at a suitable temperature for a suitable time. By a suitable temperature is meant a temperature which induces the transformation of starting material to product without decomposing any of these compounds. Examples of such suitable temperatures include, but are not limited to, room temperature and above. By a suitable ~o time is meant a time that results in high conversion of the starting material into product without causing any decomposition of either compounds, i.e. results in a good yield. This suitable time will vary depending on the temperature used in a way well known to people in the art. The higher the temperature, the shorter time is needed to give the desired conversion. The amount of water is not crucial and will depend on the process conditions ~s used. The magnesium salt of S-omeprazole trihydrate is thereafter separated from the aqueous slurry, for example by filtration or centrifugation and thereafter dried to constant weight; or b) oxidizing 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-~o benzimidazole, with an oxidizing agent and a chiral titanium complex, optionally in the presence of a base. The oxidation is carried out in an organic solvent, for example toluene or dichloromethane.
The crude product is converted to the corresponding potassium salt by treatment with a potassium source, such as methanolic potassium hydroxide or methanolic potassium methylate, followed by isolation of the formed salt.
The resulting potassium salt of S-omeprazole is thereafter converted to the corresponding magnesium salt by treatment with a magnesium source, such as magnesium sulfate in a lower alcohol, such as methanol. The solution is optionally filtered and the precipitation is ~o initialized by addition of a non-solvent such as acetone. The product is filtered off and optionally washed with water and further processed as is described in a) above.
Alternatively, the potassium salt may be treated with a magnesium source, such as magnesium sulfate in water, and isolation of the magnesium salt of S-omeprazole trihydrate, or any other conventional technique for transforming a potassium salt to the ~s corresponding magnesium salt can be used and is within the scope of the present invention.
Yet a further aspect of the present invention is to provide a suitable intermediate used in the preparation of the compound of the invention, as well as a process for its preparation.
The potassium salt of S-omeprazole is found to be such a suitable intermediate. The 2o potassium salt of S-omeprazole may also be used as an active component of a pharmaceutical formulation to be used in the treatment of gastrointestinal diseases.
The compound of the invention, i.e. the magnesium salt of S-omeprazole trihydrate , prepared according to the present invention may be analyzed by XRPD, a technique which zs is known per se.
The amount of water in the magnesium salt of S-omeprazole trihydrate is determined by thermogravimetric analysis, a technique which is known per se.
The compound of the invention is effective as a gastric acid secretion inhibitor, and is useful as an antiulcer agent. In a more general sense, it can be used for prevention and treatment of gastric-acid related conditions in mammals and especially in man, including e. g. reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, s it may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, and in patients with gastrinomas. The compound of the invention may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre- and postoperatively to ~o prevent aspiration of gastric acid and to prevent and treat stress ulceration. Further, the compound of the invention may be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections and diseases related to these. The compound of the invention may also be used for treatment of inflammatory conditions in mammals, including man.
as Any suitable route of administration may be employed for providing the patient with an effective dosage of the magnesium salt of S-omeprazole trihydrate, according to the invention. For example, peroral or parental formulations and the like may be employed.
Dosage forms include capsules, tablets, dispersions, suspensions and the like.
zo It is further provided a pharmaceutical composition comprising the magnesium salt of S-omeprazole trihydrate according to the invention, as active ingredient, in association with a pharmaceutically acceptable carrier, diluent or excipient and optionally other therapeutic ingredients. Compositions comprising other therapeutic ingredients are especially of 2s interest in the treatment of Helicobacter infections. The invention also provides the use of the magnesium salt of S-omeprazole trihydrate of the invention in the manufacture of a medicament for use in the treatment of a gastric-acid related condition and a method of treating a gastric-acid related condition which method comprises administering to a subject suffering from said condition a therapeutically effective amount of the magnesium salt of 3o S-omeprazole trihydrate according to the invention.
23940-1126(S) The compositions of the invention include compositions suitable for peroral or parental administration. The most preferred route is the oral route. The compositions may be conveniently presented in unit dosage forms, and prepared by any methods known in the art of pharmacy.
In the practice of the invention, the most suitable route of administration as well as the magnitude of a therapeutic dose of the magnesium salt of S-omeprazole trihydrate according to the invention in any given case will depend on the nature and severity of the ~o disease to be treated. The dose, and dose frequency, may also vary according to the age, body weight, and response of the individual patient. Special requirements may be needed for patients having Zollinger-Ellison syndrome, such as a need for higher doses than the average patient. Children and patients with liver diseases generally will benefit from doses that are somewhat lower than the average. Thus, in some conditions it may be necessary to ~s use doses outside the ranges stated below, for example long term treatments may request lower dosage. Such higher and lower doses are within the scope of the present invention.
Such daily doses may vary between 5 mg to 300 mg.
In general, a suitable oral dosage form of the compound of the invention may cover a dose ~o range from 5 mg to 300 mg total daily dose, administered in one single dose or equally divided doses. A preferred dosage range is from 10 mg to 80 mg.
The compound of the invention may be combined as the active component in intimate admixture with a pharmaceutical carrier according to conventional techniques, such as the 's oral formulations described in WO 96/01623 and EP 247 983.
Combination preparations comprising the magnesium salt of S-omeprazole trihydrate and other active ingredients may also be used. Examples of such active ingredients include, but 23940-1126(S) 8.
are not limited to anti-bacterial compounds, non-steroidal anti-inflammatory agents, antacid agents, alginates and prokinetic agents.
In a further aspect, the invention provides a commercial package comprising the magnesium salt of S-omeprazole trihydrate of the invention or a pharmaceutical composition thereof and associated therewith instructions for the use thereof in the treatment of a gastric acid related condition in a subject suffering from the condition.
The examples which follow will further illustrate the preparation of the compound of the invention, according to different process routes and including new intermediates. These examples are not intended to limit the scope of the invention as defined hereinabove or as claimed below.
Examples ~s ao Example I
S-S-methoxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)-methylJsulfzrcylJ 1H-benzimidazole magnesium salt trihydrate Water ( 157 kg) was added to the wet crystals of the magnesium salt of S-omeprazole, prepared according to Example 4, below. The mixture was heated to 38°C
with stirring and left for 3 hours. The crystals were filtered off and dried in vacuo. Yield:
31.6 kg '-s X-ray powder diffraction analysis was performed on a sample of the crystals prepared above according to standard methods, which can be found in e.g. Kitaigorodsky, A. I.
( 1973), Molecular Crystals and Molecules, Academic Press, New York; Bunn, C.
W.
( 1948), Chemical Crystallography, Clarendon Press, London; or Klug, H.P. &
Alexander, L. E. ( 1974), X-Ray Diffraction Procedures, John Wiley and Sons, New York.
The analysis gave the diffractogram depicted in Figure 1. The main peaks, with positions and relative intensities, have been extracted from the diffractogram in Figure 1 and is given below in table 1. The relative intensities are less reliable and instead of numerical values the following definitions are used.
% Relative Intensity Definition 25-100 vs (very strong) 10-25 s (strong) 3-10 m (medium) s 1-3 w (weak) < 1 vw (very weak) Some additional very weak peaks found in the diffractogram have been omitted from table 1.
~o Table 1. Positions and intensities of the major peaks in the XRP-diffractogram of the magnesium salt of S-omeprazole trihydrate.
d-value Relative l ~ i L
i 2.67 ~ m 2.79 ~ m 3.27 m i 3.52 ~ s 3.82 ~ s i 3.96 ~ vs 4.14 w m i 5.2 ~ m i 5.6 ~ m i 6.7 i vs i 6.9 I s t 8.3 ; w 16.6 vs Example 2 S-5-methaxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)methylJsulfinylJ-IH-benzimidazole potassium salt s A solution of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-benzimidazole (15.4 g, 46.8 mmol) in toluene {70 ml) was heated to 50°C
and water (0.05 ml, 2,8 mmol) and D-(-)-diethyl tartrate (2.02 g, 9.82 mlnol) were added. The reaction mixture was stirred for 20 minutes. Titanium(IV)isopropoxide ( 1.34 g, 4.68 mmol) was io added and the reaction mixture was stirred for 45 minutes. The mixture was cooled to 30°C
and diisopropylethylamine (0.91 g, 7.01 mmol) was added followed by cumene hydroperoxide (9.52 g, 51.89 mmol). The resultant mixture was stirred at 30°C for 3 hours.
Methanol (40 mI) was added followed by potassium hydroxide (3.05 g, 46.8 mmol) in methanol (30 ml). Seed crystals were added and the reaction mixture was stirred at 35°C
is overnight. The precipitated product was filtered off, washed with methanol and toluene and dried in vacuo. Yield: 9.74 g (54%).
Example 3 2o S-5-methoxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)-methylJsulfxnylJ-IH-benzimidazole potassium salt Water (157.6 p.l) was added to a solution of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyi)methyl]thio]-1H-benzimidazole in toluene (370 ml; 211.5 g/1) with a water zs content of 0.031 % (w/w), followed by addition of D-(-)-diethyl tartrate (8.55 ml). The solution was heated to 50°C and stirred at this temperature for 20 minutes.
Titanium(IV)isopropoxide (7.15 ml) was added and reaction was left at 50°C for 45 minutes. The temperature was lowered to 30°C and diisopropylethyiamine (6.2 ml) was added. Cumene hydroperoxide was added at an appropriate speed to maintain the so temperature from 28°C to 34°C. The temperature was raised to 35°C after 2 hours and potassium methoxide (24.55 g) in methanol (222 ml) was added. The mixture was filtered after 14 hours and the crystals were washed with methanolaoluene (240 ml; l:l) and methanol (120 ml) and dried. Yield: 79 g (74%), ee > 99.9%.
a = +28.7 c = 1 %, water ; Assa : 89% is S-5-methox -2 4-methox -3,5-L JD2~ ° { ) Y Y -LE{ Y
s dimethyl-2-pyridinyl)-methyl]sulfinyl]-IH-benzimidazole potassium salt (l l%
is methanol).
1H-NMR (200 MHz, DMSO-db, 8 ppm): 2.23 (s, 3H), 2.24 (s, 3H), 3.71 (s, 3H), 3.75 {s, 3H), 4.40 (d, 1H), 4.78 (d, IH), 6.58 (dd, 1H), 7.00 (d, 1H), 7.35 (d, 1H), 8.25 {s, 1H).
~o The products from Examples 2 and 3 were analysed using X-ray powder diffraction as described in Example 1 and gave the diffractogram depicted in Figure 2 and given below in Table 2. Some additional very weak peaks found in the diffractogram have been omitted from Table 2.
is Table 2. Positions and intensities of the major peaks in the XRP-diffractograrn of the potassium salt of S-omeprazole.
d-value/A Relatived-value/ Relative intensit(~) intensit 13.6 vs 3.52 m 10.6 vw 3.42 w 7.8 m I 3.38 w 6.8 m 3.34 m 6.5 m 3.28 w 6.2 w 3.20 m 6.1 m ~ 3.12 w 5.8 s 3.06 w 5.4 m I 3.03 w 5.3 w 2.97 w oc 1 = 1.54060 A
5.2 w 2.93 vw 5.0 vw 2.89 w 4.75 m 2.85 m 4.71 w 2.76 w 4.52 w 2.71 vw 4.42 w ~ 2.66 . vw 4.32 w 2.58 w 4.27 m ~ 2.57 w 3.98 vw I 2.56 w 3.92 w 2.52 vw 3.89 w ~ 2.47 vw 3.87 w 2.45 vw 3.81 w 2.43 vw 3.74 m 1 2.40 vw 3.60 m 1 2.38 vw 3.55 ~ m I 2.31 vw Example 4 S-S-methoxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)-methylJsulfinylJ-IH-benzimidazole magnesium salt s Methanol ( 148 kg) was added to S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-IH-benzimidazole potassium salt (71 kg, methanol content =
13%).
MgS04 x 7 H20 (40 kg) was added to the mixture while stirring. After 70 minutes the mixture was filtered and the filtrate was washed with methanol (46 kg). The solution was io concentrated to a volume of 100 liter, acetone (253 kg) was added and the resulting mixture was left for 4 hours. The precipitated product was filtered off, washed with acetone and water. The wet crystals were immediately used as is described in Example 1.
Example 5 ~s S-5-methoxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)-methylJsulftnylJ-IH
benzimidazole magnesium salt dehydrate 5.0 g of the moist product from Example 4 with an approximate dry content of 74%, was 2o dried in vacuum at 35 °C over night to yield 3.58 g (2.68 mmol) of S-5-methoxy-2-[[(4-methoxy-3,S-dimethyi-2-pyridinyl)-methylJsulflnyl]-1H-benzimidazole magnesium salt dehydrate, named Form B.
The product was analyzed using X-ray powder diffraction as described in Example l, and 2s the analyze gave the diffractogram depicted in Figure 3 and given below in Table 3. Some additional peaks with low intensities found in the diffractogram have been omitted from Table 3.
Table 3. Positions and intensities of the major peaks in the XRP-diffractogram of the magnesium salt of S-omeprazole dehydrate, Form B.
d-value / A Relative Intensit 4.19 m 4.45 m 4.68 m 4.79 s 4.91 s 4.98 s 5.1 m 5.4 s 5.5 m 5.6 m 5.8 m 6.3 m 6.7 s 7.9 m 8.1 s i 1.0 m 11.8 m 14.9 vs Convertion of magnesium salt of S-omeprazole dehydrate to trihydrate This material was subsequently processed to S-S-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt trihydrate according to the procedure described for the moist substance in Example 1.
WO 98/54171 PCTlSE98/00974 Example 6 S-5-methoxy-2-~((4-methoxy-3,5-dimethyl-2 pyridinyl)-methylJsul~nylJ-IH-benzimidazole magnesium salt dehydrate A methanolic solution of S-S-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinylJ-IH-benzimidazole magnesium salt was prepared as is described in Example 4. Such a solution of S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulflnyl]-IH-benzimidazole magnesium salt (1.86g) in 5 mI methanol was io concentrated by evaporation until I.58 ml methanol remained. Then, a mixture of 1.6 ml water and 6.32 rnl aceton was added. The solution was allowed to crystallize during 26 h at room temperature. The resulting crystals were filtered off and dried at 40 °C under reduced pressure giving 1.17 g of S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfmylJ-1H-benzimidazole magnesium salt dehydrate, named form A.
is The product was analyzed using X-ray powder diffration as described in Example 1 and gave the diffractogram depicted in Figure 4 and given below in Table 4. Some additional peaks with low intensities found in the diffractogram have been omitted from Table 4.
zo Table 4. Positions and intensities of the major peaks in the XRP-diffractogram of the magnesium salt of S-omeprazole dehydrate, Form A.
d-value / A Relative Intensit 3.04 s 3.14 s 3.18 m 4.05 s 4.19 s 4.32 m 4.54 s 4.69 vs 5.2 s 5.3 s 5.8 s 6.2 vs 6.6 s 15.5 vs Example 7 S-S-methoxy-2-jj(4-methoxy-3,S-dimethyl-2 pyridinyl)-methylJsul~nylJ-1H-s benzimidazole magnesium salt trihydrate 22,0 g (29,1 mmol) of S-5-methoxy-2-[[{4-methoxy-3,5-dimethyl-2-pyridinyl) methyl]sulfinyl]-1H-benzimidazole potassium salt was dissolved in 40 mL of water. The solution was seeded with 0,11 g (0,1 mmol) S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-~o pyridinyl)-methyl]sulfinyl]-1H-benzimidazole magnesium salt trihydrate. 22 mL (69,6 mmol) of MgS04 (aq) was added under a 3 h period. The slurry was filtered off and the precipitate was elutriated in water for approximately 30 minutes and the crystals were filtered off and dried (35 °C, vacuum).
Yield: 9,15 g ( 11,6 mmol; 80%). The substance had a purity (HPLC):99,8 area%, Mg content: 3,40 % (w/w) and ee: 99,8%.
The product was analyzed using X-ray powder diffraction and the result complies with s Figure 1 and Table 1.
Reference Example A
S-5-methoxy-2-jj(4-methoxy-3,5-dimethyl-2 pyridinyl)-methyl)sulJinylJ-IH-~o benzimidazole magnesium salt (The method used is in accordance with the method described in Example A in WO
96/01623) ~s Magnesium (0.1 lg, 4.5 mmol) was dissolved and reacted with methanol (SO
ml) at 40°C
with a catalytic amount of methylene chloride. The reaction was run under nitrogen and was finished after five hours. At room temperature a mixture of the two enantiomers [90%(-)-isomer and 10%(+)-isomer] of 5-methoxy-2-([(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulflnyl]-1H-benzimidazole (2.84 g, 8.2 mmoi) was added to the zo magnesium methoxide solution. The mixture was stirred for 12 hours whereupon a small amount of water (0.1 ml) was added in order to precipitate inorganic magnesium salts.
After 30 minutes stirring, these inorganic salts were filtered off and the solution was concentrated on a rotavapor. The residue was now a concentrated methanolic solution of the enantiomeric mixture (i.e. the title compound contaminated with the (+)-isomer), with zs an optical purity (enantiomeric excess, e-e.) of 80%. This mixture was diluted with acetone ( 100 ml) and after stirring at room temperature for 15 minutes, a white precipitate was obtained. Additional stirring for 15 minutes and thereafter filtration afforded 1.3 .g (50%) of the title compound as white crystals. Chiral analyses of the crystals and mother liquor were performed by chromatography on an analytical chiral column. The optical purity of the so crystals and mother liquor was found to be 98.4 e-e. and 64.4% e-e., respectively. Thus, the optical purity e.e.) has been enhanced from 80% to 98.4% simply by crystallizing the Mg-salt from a mixture of acetone and methanol. The product was crystalline as shown by powder X-ray diffraction and the magnesium content was 3.44% as shown by atomic absorption spectroscopy. [oc]D20 _131.5° (c=0.5%, methanol).
The product was analyzed using X-ray powder diffraction as described in Example 1 and gave the diffractogram depicted in Figure 5 and given below in Table 5. Some additional very weak peaks found in the diffractograms have been omitted from Table 5.
Table 5. Positions and intensities of the major peaks in the XRP-diffractogram shown in Figure 5.
i d-value Relative Intensi l ~ ;
E
2.90 ~ s 3.41 j s 3.90 ~ s 4.i3 ~ s 4.79 ' vs 5.00 i vs 5.4 ~ vs 5.7 ~ s 6.3 s 6.8 s 7.8 s 8.4 ~ vs I0.8 $ s 12.2 s 15.1 vs
Claims (14)
1. The magnesium salt of S-omeprazole trihydrate.
2. The magnesium salt of S-omeprazole trihydrate according to claim 1, characterized by being highly crystalline.
3. The magnesium salt of S-omeprazole trihydrate according to claim 1 characterized by being stable.
4. The magnesium salt of S-omeprazole trihydrate according to claim 1, characterized by the following major peaks in its X-ray powder diffractogram :
5. A process for the preparation of the magnesium salt of S-omeprazole trihydrate according to any one of claims 1 to 4 comprising treating a magnesium salt of S-omeprazole, other than the magnesium salt of S-omeprazole trihydrate, with water.
6. A process for the preparation of the magnesium salt of S-omeprazole trihydrate according to any one of claims 1 to 4 comprising steps of:
a) mixing a potassium salt of S-omeprazole with an organic solvent;
b) converting the potassium salt of S-omeprazole into a corresponding magnesium salt of S-omeprazole by treating the said potassium salt with a magnesium source;
c) precipitating the magnesium salt of S-omeprazole by addition of a non-solvent;
d) isolating the precipitated magnesium salt of S-omeprazole;
e) treating the isolated magnesium salt of S-omeprazole with water to obtain a magnesium salt of S-omeprazole trihydrate; and f) isolating and drying the magnesium salt of S-omeprazole trihydrate obtained in step e).
a) mixing a potassium salt of S-omeprazole with an organic solvent;
b) converting the potassium salt of S-omeprazole into a corresponding magnesium salt of S-omeprazole by treating the said potassium salt with a magnesium source;
c) precipitating the magnesium salt of S-omeprazole by addition of a non-solvent;
d) isolating the precipitated magnesium salt of S-omeprazole;
e) treating the isolated magnesium salt of S-omeprazole with water to obtain a magnesium salt of S-omeprazole trihydrate; and f) isolating and drying the magnesium salt of S-omeprazole trihydrate obtained in step e).
7. A process according to claim 6, wherein said organic solvent used in step a) is methanol.
8. A process according to claim 6 or 7, wherein the said non-solvent used in step c) is acetone.
9. A process for the preparation of the magnesium salt of S-omeprazole trihydrate according to any one of claims 1 to 4 comprising steps of:
i) converting a potassium salt of S-omeprazole into a corresponding magnesium salt of S-omeprazole by treating said potassium salt with a magnesium source in water to obtain the magnesium salt of S-omeprazole trihydrate; and ii) isolating and drying the magnesium salt of S-omeprazole trihydrate obtained in step i).
i) converting a potassium salt of S-omeprazole into a corresponding magnesium salt of S-omeprazole by treating said potassium salt with a magnesium source in water to obtain the magnesium salt of S-omeprazole trihydrate; and ii) isolating and drying the magnesium salt of S-omeprazole trihydrate obtained in step i).
10. A process according to any one of claims 6 to 9, wherein the said magnesium source is magnesium sulfate.
11. A pharmaceutical composition comprising the magnesium salt of S-omeprazole trihydrate according to any one of claims 1 to 4 as active ingredient in association with a pharmaceutically acceptable carrier.
12. Use of the magnesium salt of S-omeprazole trihydrate according to any one of claims 1 to 4, or the composition according to claim 11 in the manufacture of a medicament for use in the treatment of a gastric acid related condition in a subject suffering from the condition.
13. Use of the magnesium salt of S-omeprazole trihydrate according to any one of claims 1 to 4, or the composition according to claim 11 in the treatment of a gastric acid related condition in a subject suffering from the condition.
14. A commercial package comprising the magnesium salt of S-omeprazole trihydrate according to any one of claims 1 to 4, or the composition according to claim 11, and associated therewith instructions for the use thereof in the treatment of a gastric acid related condition in a subject suffering from the condition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002521391A CA2521391C (en) | 1997-05-30 | 1998-05-25 | Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9702065A SE510650C2 (en) | 1997-05-30 | 1997-05-30 | New association |
| SE9702065-5 | 1997-05-30 | ||
| PCT/SE1998/000974 WO1998054171A1 (en) | 1997-05-30 | 1998-05-25 | Novel form of s-omeprazole |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002521391A Division CA2521391C (en) | 1997-05-30 | 1998-05-25 | Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2290963A1 CA2290963A1 (en) | 1998-12-03 |
| CA2290963C true CA2290963C (en) | 2006-03-28 |
Family
ID=20407186
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002521391A Expired - Lifetime CA2521391C (en) | 1997-05-30 | 1998-05-25 | Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate |
| CA002290963A Expired - Lifetime CA2290963C (en) | 1997-05-30 | 1998-05-25 | S-omeprazole magnesium trihydrate |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002521391A Expired - Lifetime CA2521391C (en) | 1997-05-30 | 1998-05-25 | Potassium salt of s-omeprazole as intermediate in the preparation of the magnesium salt of s-omeprazole trihydrate |
Country Status (44)
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6875872B1 (en) * | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
| SE9301830D0 (en) * | 1993-05-28 | 1993-05-28 | Ab Astra | NEW COMPOUNDS |
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| DK0909323T3 (en) | 1996-01-04 | 2007-05-21 | Novartis Vaccines & Diagnostic | Helicobacter pylori bacterioferritin |
| SE510650C2 (en) * | 1997-05-30 | 1999-06-14 | Astra Ab | New association |
| SE9900274D0 (en) * | 1999-01-28 | 1999-01-28 | Astra Ab | New compound |
| US6369087B1 (en) * | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US6316020B1 (en) | 1999-08-26 | 2001-11-13 | Robert R. Whittle | Pharmaceutical formulations |
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| AU2003208686A1 (en) | 2002-03-05 | 2003-09-16 | Astrazeneca Ab | Alkylammonium salts of omeprazole and esomeprazole |
| AU2003262375A1 (en) * | 2002-04-22 | 2003-11-03 | Sun Pharmaceutical Industries Limited | Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts |
| WO2004002982A2 (en) * | 2002-06-27 | 2004-01-08 | Dr. Reddy's Laboratories Limited | A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof |
| AU2003247729B2 (en) * | 2002-06-27 | 2009-10-08 | Dr. Reddy's Laboratories Limited | A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof |
| TW200410955A (en) | 2002-07-29 | 2004-07-01 | Altana Pharma Ag | Novel salt of (S)-PANTOPRAZOLE |
| WO2004020436A1 (en) * | 2002-08-30 | 2004-03-11 | Reddy's Laboratories Limited | Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof |
| EP2596792A1 (en) * | 2002-10-16 | 2013-05-29 | Takeda Pharmaceutical Company Limited | Stable solid preparations |
| AU2003278406A1 (en) * | 2002-10-22 | 2004-05-13 | Ranbaxy Laboratories Limited | Amorphous form of esomeprazole salts |
| WO2004046134A2 (en) * | 2002-11-18 | 2004-06-03 | Dr. Reddy's Laboratories Limited | Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation |
| WO2004060263A2 (en) * | 2003-01-07 | 2004-07-22 | Ranbaxy Laboratories Limited | Magnesium salt of imidazole derivative |
| WO2004089935A1 (en) * | 2003-04-10 | 2004-10-21 | Hetero Drugs Limitd | Novel crystalline forms of s-omeprazole magnesium |
| US20070060556A1 (en) | 2003-05-05 | 2007-03-15 | Yatendra Kumar | Barium salt of benzimidazole derivative |
| US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| ATE386522T1 (en) * | 2003-07-23 | 2008-03-15 | Nycomed Gmbh | ALKALINE SALTS OF PROTON PUMP INHIBITORS |
| CN100457104C (en) * | 2003-07-23 | 2009-02-04 | 尼科梅德有限责任公司 | Alkaline salts of proton pump inhibitors |
| SE0302381D0 (en) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts I |
| SE0302382D0 (en) | 2003-09-04 | 2003-09-04 | Astrazeneca Ab | New salts II |
| US20050075371A1 (en) * | 2003-10-03 | 2005-04-07 | Allergan, Inc. | Methods and compositions for the oral administration of prodrugs of proton pump inhibitors |
| US20070292498A1 (en) * | 2003-11-05 | 2007-12-20 | Warren Hall | Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers |
| AU2005216862A1 (en) * | 2004-02-18 | 2005-09-09 | Allergan, Inc. | Compositions comprising prodrugs of proton pump inhibitors |
| CA2557471A1 (en) * | 2004-02-18 | 2005-09-09 | Allergan, Inc. | Methods and compositions for the intravenous administration of compounds related to proton pump inhibitors |
| US20050239845A1 (en) * | 2004-04-16 | 2005-10-27 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and prokinetic agent |
| US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
| US20050267159A1 (en) * | 2004-05-28 | 2005-12-01 | Aaipharma, Inc. | Magnesium complexes of S-omeprazole |
| US20050267157A1 (en) * | 2004-05-28 | 2005-12-01 | David White | Magnesium-S-omeprazole |
| US8461187B2 (en) | 2004-06-16 | 2013-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
| WO2006001753A1 (en) * | 2004-06-24 | 2006-01-05 | Astrazeneca Ab | New process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt |
| ES2246149B1 (en) * | 2004-07-02 | 2007-06-01 | Esteve Quimica, S.A. | SOLID FORMS OF S-OMEPRAZOL MAGNETIC SALT AND PROCEDURES FOR PREPARATION. |
| US20060024362A1 (en) * | 2004-07-29 | 2006-02-02 | Pawan Seth | Composition comprising a benzimidazole and process for its manufacture |
| WO2006073779A1 (en) * | 2004-12-30 | 2006-07-13 | Transform Phamaceuticals, Inc. | Novel omeprazole forms and related methods |
| ES2259269B1 (en) | 2005-03-03 | 2007-11-01 | Esteve Quimica, S.A. | PROCEDURE FOR THE PREPARATION OF DERIVATIVES OF 2- (2-PIRIDILMETILSULFINIL) -BENCIMIDAZOL OPTICALLY ACTIVE. |
| US20060210637A1 (en) * | 2005-03-17 | 2006-09-21 | Qpharma, Llc | Stable tablet dosage forms of proton pump inhibitors |
| US20090298884A1 (en) * | 2005-05-06 | 2009-12-03 | Glenmark Generics Ltd. | Esomeprazole Strontium Salt, Process For Its Preparation and Pharmaceutical Compositions Containing Same |
| US7563812B2 (en) | 2005-06-15 | 2009-07-21 | Hetero Drugs Limited | Amorphous esomeprazole hydrate |
| EP1904064A4 (en) * | 2005-07-07 | 2009-12-02 | Reddys Lab Ltd Dr | Omeprazole form b |
| KR100641534B1 (en) | 2005-07-28 | 2006-11-01 | 한미약품 주식회사 | Process of esomeprazole and salts thereof |
| US20070026071A1 (en) * | 2005-07-28 | 2007-02-01 | Qpharma, Llc | Magnesium salt proton pump inhibitor dosage forms |
| WO2007031845A2 (en) * | 2005-09-14 | 2007-03-22 | Glenmark Pharmaceuticals Limited | Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation |
| AU2006299424A1 (en) * | 2005-10-06 | 2007-04-12 | Auspex Pharmaceuticals, Inc. | Deuterated inhibitors of gastric H+, K+-ATPase with enhanced therapeutic properties |
| US7576219B2 (en) * | 2005-10-26 | 2009-08-18 | Hanmi Pharm. Co., Ltd | Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same |
| CA2626085C (en) * | 2005-10-26 | 2011-12-06 | Hanmi Pharm. Co., Ltd. | S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same |
| EP1801110A1 (en) | 2005-12-22 | 2007-06-27 | KRKA, tovarna zdravil, d.d., Novo mesto | Esomeprazole arginine salt |
| US7553857B2 (en) * | 2005-12-23 | 2009-06-30 | Lek Pharmaceuticals D.D. | S-omeprazole magnesium |
| CN100384839C (en) * | 2006-02-17 | 2008-04-30 | 中国科学院上海有机化学研究所 | Prepn process of [(substituted pyridyl) methyl] sulfenyl-1H-benzimidazole compound and its antimer zinc salt |
| US7579476B2 (en) * | 2006-02-24 | 2009-08-25 | Praktikatalyst Pharma, Llc | Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals |
| US8063074B2 (en) | 2006-05-04 | 2011-11-22 | Dr. Reddy's Laboratories Limited | Polymorphic forms of esomeprazole sodium |
| EP2040710A2 (en) * | 2006-06-21 | 2009-04-01 | Glenmark Pharmaceuticals Limited | Novel polymorph of esomeprazole potassium and process for its preparation |
| WO2008067037A2 (en) | 2006-10-05 | 2008-06-05 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| US20080103169A1 (en) | 2006-10-27 | 2008-05-01 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
| EP1947099A1 (en) * | 2007-01-18 | 2008-07-23 | LEK Pharmaceuticals D.D. | Process for solvent removal from omeprazole salts |
| EA200900985A1 (en) | 2007-01-31 | 2009-12-30 | Крка, Товарна Здравил, Д. Д., Ново Место | METHOD OF OBTAINING OPTICAL PURE OMEPRAZOL |
| EP2125783A2 (en) * | 2007-02-21 | 2009-12-02 | Cipla Limited | Process for the preparation of esomeprazole magnesium dihydrate |
| KR101303813B1 (en) * | 2007-04-16 | 2013-09-04 | 에스케이케미칼주식회사 | Improved preparing method of (S)-omeprazole from omeprazole racemate using optical resolution agent |
| EP2000468A1 (en) | 2007-05-09 | 2008-12-10 | Dr. Reddy's Laboratories Ltd. | Esomeprazole salts and processes for preparation thereof |
| US8492551B2 (en) * | 2007-06-07 | 2013-07-23 | Aurobindo Pharma. Ltd. | Process for preparing an optically active proton pump inhibitor |
| FR2920428B1 (en) * | 2007-08-29 | 2012-06-15 | Univ Rouen | PROCESS FOR DEDOLDING SALTS OF OMEPRAZOLE |
| US8106210B2 (en) * | 2007-10-08 | 2012-01-31 | Hetero Drugs Limited | Polymorphs of esomeprazole salts |
| KR20150084013A (en) | 2007-10-12 | 2015-07-21 | 다케다 파마슈티칼스 유에스에이, 인코포레이티드 | Methods of treating gastrointestinal disorders independent of the intake of food |
| WO2009074997A2 (en) * | 2007-12-10 | 2009-06-18 | Lee Pharma Ltd. | A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate |
| WO2009099933A2 (en) * | 2008-02-01 | 2009-08-13 | Dr. Reddy's Laboratories Ltd. | Preparation of esomeprazole magnesium and hydrates thereof |
| US20090280173A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Omeprazole Tablets |
| US20090280175A1 (en) * | 2008-05-09 | 2009-11-12 | Ishwar Chauhan | Multilayer Proton Pump Inhibitor Tablets |
| EP2143722A1 (en) | 2008-07-09 | 2010-01-13 | Lek Pharmaceuticals D.D. | Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium |
| EP2147918A1 (en) * | 2008-07-21 | 2010-01-27 | LEK Pharmaceuticals D.D. | Process for the preparation of S-omeprazole magnesium in a stable form |
| EP2344139A1 (en) | 2008-09-09 | 2011-07-20 | AstraZeneca AB | Method for delivering a pharmaceutical composition to patient in need thereof |
| CN101391993B (en) * | 2008-10-28 | 2012-07-04 | 安徽美诺华药物化学有限公司 | Method for preparing S-omeprazole and salt thereof by forming inclusion complex with (S)-(-)-1,1'-dinaphthalene-2,2'-diol |
| WO2010097583A1 (en) | 2009-02-24 | 2010-09-02 | Cipla Limited | Esomeprazole potassium polymorph and its preparation |
| US20100267959A1 (en) * | 2009-04-15 | 2010-10-21 | Glenmark Generics Limited | Process for the preparation of esomeprazole magnesium dihydrate |
| WO2010122583A2 (en) | 2009-04-24 | 2010-10-28 | Rubicon Research Private Limited | Oral pharmaceutical compositions of acid labile substances |
| WO2010150276A2 (en) * | 2009-06-02 | 2010-12-29 | Sun Pharmaceutical Industries Limited | Process for preparing sulphoxide compounds |
| SG176724A1 (en) | 2009-06-25 | 2012-01-30 | Astrazeneca Ab | Method for treating a patient at risk for developing an nsaid-associated ulcer |
| JP2012531430A (en) * | 2009-06-25 | 2012-12-10 | ポーゼン インコーポレイテッド | Methods for treating patients in need of aspirin therapy |
| WO2011012957A1 (en) * | 2009-07-29 | 2011-02-03 | Orchid Chemicals & Pharmaceuticals Ltd | An improved process for the preparation of esomeprazole magnesium dihydrate |
| EP2499125B1 (en) | 2009-11-12 | 2016-01-27 | Hetero Research Foundation | Process for the resolution of omeprazole |
| US8895271B2 (en) | 2009-12-08 | 2014-11-25 | Codexis, Inc. | Synthesis of prazole compounds |
| US20110207779A1 (en) * | 2010-02-25 | 2011-08-25 | Glenmark Generics Ltd | Process for the preparation of esomeprazole magnesium |
| FR2959509B1 (en) | 2010-05-03 | 2012-07-13 | Prod Chim Auxiliaires Et De Synthese | PRECURSOR PHASE AND USE THEREOF FOR PREPARING MAGNESIUM TETRAHYDRATE SALT OF AN OMEPRAZOLE ENANTIOMER |
| CN102241668B (en) * | 2010-05-11 | 2015-11-25 | 中国科学院成都有机化学有限公司 | Esomprazole salt |
| US9267159B2 (en) | 2010-12-08 | 2016-02-23 | Codexis, Inc. | Biocatalysts and methods for the synthesis of armodafinil |
| CN102757421A (en) * | 2011-04-29 | 2012-10-31 | 江苏正大天晴药业股份有限公司 | Purification method of esomeprazole |
| CN102911158B (en) * | 2011-07-31 | 2015-07-22 | 连云港润众制药有限公司 | Crystal form of esomeprazole magnesium |
| CN102924435B (en) * | 2011-11-25 | 2014-06-25 | 成都自豪药业有限公司 | Novel crystal form of S-omeprazole magnesium salt and preparing method thereof |
| WO2013088272A1 (en) * | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Pharmaceutical composition comprising esomeprazole magnesium dihydrate |
| EP2797600A4 (en) | 2011-12-28 | 2015-09-16 | Pozen Inc | Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| CN102584792B (en) * | 2012-01-06 | 2014-06-11 | 南京优科生物医药研究有限公司 | Method for preparing high-purity esomeprazole |
| CN102993184A (en) * | 2013-01-08 | 2013-03-27 | 湖南方盛制药股份有限公司 | Esomeprazole and preparation method of magnesium trihydrate of esomeprazole |
| CN104250243B (en) * | 2013-06-27 | 2016-12-28 | 四川国为制药有限公司 | A kind of preparation method of Esomeprazole magnesium dihydrate A crystal formation |
| CN103570686B (en) * | 2013-10-14 | 2015-04-01 | 哈药集团技术中心 | Method for synthesizing and refining esomeprazole sodium |
| CN104725357A (en) * | 2013-12-24 | 2015-06-24 | 苏州联友制药技术有限公司 | Preparation method of esomeprazole magnesium dihydrate crystal form B |
| FR3018812A1 (en) * | 2014-03-21 | 2015-09-25 | Minakem | NOVEL INTERMEDIATE PHASE OF FORM A OF MAGNESIUM SALT DIHYDRATE OF AN OMEPRAZOLE ENANTIOMER |
| CN104447699A (en) * | 2014-12-10 | 2015-03-25 | 哈药集团技术中心 | Preparation method of esomeprazole magnesium trihydrate |
| CN105111188B (en) * | 2015-08-19 | 2018-01-19 | 扬子江药业集团有限公司 | A kind of preparation method of esomeprazole magnesium trihydrate crystal formation |
| US10736855B2 (en) | 2016-02-25 | 2020-08-11 | Dexcel Pharma Technologies Ltd. | Compositions comprising proton pump inhibitors |
| CN106397402B (en) * | 2016-08-30 | 2019-05-03 | 山东罗欣药业集团股份有限公司 | A kind of esomeprazole magnesium crystal-form compound and preparation method thereof |
| KR102080023B1 (en) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | Stable pharmaceutical composition comprising esomeprazole and sodium bicarbonate |
| KR102006777B1 (en) | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | Pharmaceutical formulation comprising esomeprazole and sodium bicarbonate |
| KR102432084B1 (en) | 2021-11-16 | 2022-08-12 | 알리코제약(주) | S-omeprazole tablet having improved stability and miniaturized size |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (en) | 1978-04-14 | 1979-10-15 | Haessle Ab | Gastric acid secretion |
| SE8301182D0 (en) | 1983-03-04 | 1983-03-04 | Haessle Ab | NOVEL COMPOUNDS |
| US5244891A (en) | 1985-08-05 | 1993-09-14 | Bristol-Myers Squibb Company | Injectable compositions of cefepime dihydrochloride hydrate |
| GB2189698A (en) | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated omeprazole tablets |
| US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| DE4035455A1 (en) | 1990-11-08 | 1992-05-14 | Byk Gulden Lomberg Chem Fab | ENANTIOMER SEPARATION |
| US5360582A (en) | 1991-07-15 | 1994-11-01 | Minnesota Mining And Manufacturing Company | Nonlinear optical materials containing polar disulfone-functionalized molecules |
| US5877192A (en) | 1993-05-28 | 1999-03-02 | Astra Aktiebolag | Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole |
| SE9301830D0 (en) * | 1993-05-28 | 1993-05-28 | Ab Astra | NEW COMPOUNDS |
| SE9302396D0 (en) * | 1993-07-09 | 1993-07-09 | Ab Astra | A NOVEL COMPOUND FORM |
| SE9302395D0 (en) * | 1993-07-09 | 1993-07-09 | Ab Astra | NEW PHARMACEUTICAL FORMULATION |
| FR2719045B1 (en) * | 1994-04-20 | 1996-05-31 | Rhone Poulenc Chimie | Process for the preparation of L-aspartic acid from ammonium aspartate. |
| DE69522921T2 (en) | 1994-07-08 | 2002-04-11 | Astrazeneca Ab | DOSAGE FORM IN TABLET FORM COMPOSED FROM SEVERAL UNITS |
| FR2722191B1 (en) | 1994-07-08 | 1996-08-23 | Rhone Poulenc Rorer Sa | PROCESS FOR THE PREPARATION OF (2R, 3S) -3-TERTBUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE (2R, 3S) TRIHYDRATE, 20EPOXY-11BYA -13ALPHA-YLE |
| SE504459C2 (en) | 1994-07-15 | 1997-02-17 | Astra Ab | Process for the preparation of substituted sulfoxides |
| ATE199375T1 (en) | 1994-11-14 | 2001-03-15 | Daiichi Seiyaku Co | METHOD FOR PRODUCING 3-(2-(4-(3-CHLORINE-2-METHYLPHENYL)-1-PIPERAZINYL)ETHYL)-5,6-DIMETHOXY-1-(4-IMIDAZOLYLMETHYL)-1H-INDAZOLE-DIHYDROCHLORIDE-3.5 -HYDRATE. |
| GB9423970D0 (en) | 1994-11-28 | 1995-01-11 | Astra Ab | Oxidation |
| SE9500422D0 (en) | 1995-02-06 | 1995-02-06 | Astra Ab | New oral pharmaceutical dosage forms |
| CN1042423C (en) | 1995-05-25 | 1999-03-10 | 常州市第四制药厂 | Aomeilazole salt hydrate for gastric acid inhibitor and its preparing method |
| SE9600072D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
| SE9600070D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral pharmaceutical dosage forms |
| SE9600071D0 (en) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| US6747155B2 (en) | 1997-05-30 | 2004-06-08 | Astrazeneca Ab | Process |
| SE510650C2 (en) | 1997-05-30 | 1999-06-14 | Astra Ab | New association |
| AR057181A1 (en) | 2005-11-30 | 2007-11-21 | Astra Ab | NEW COMBINATION DOSAGE FORM |
-
1997
- 1997-05-30 SE SE9702065A patent/SE510650C2/en not_active IP Right Cessation
-
1998
- 1998-05-05 US US09/077,719 patent/US6369085B1/en not_active Expired - Lifetime
- 1998-05-15 HR HR980263A patent/HRP980263B1/en not_active IP Right Cessation
- 1998-05-18 ZA ZA984179A patent/ZA984179B/en unknown
- 1998-05-18 DZ DZ980105A patent/DZ2495A1/en active
- 1998-05-18 TW TW087107675A patent/TW538040B/en not_active IP Right Cessation
- 1998-05-18 AR ARP980102299A patent/AR012717A1/en active IP Right Grant
- 1998-05-21 MA MA25085A patent/MA26500A1/en unknown
- 1998-05-25 EP EP98926005.4A patent/EP0984957B3/en not_active Expired - Lifetime
- 1998-05-25 ME MEP-249/08A patent/MEP24908A/en unknown
- 1998-05-25 BR BR9809509-9A patent/BR9809509A/en not_active Application Discontinuation
- 1998-05-25 PT PT98926005T patent/PT984957E/en unknown
- 1998-05-25 NZ NZ500991A patent/NZ500991A/en not_active IP Right Cessation
- 1998-05-25 IL IL13294798A patent/IL132947A0/en not_active IP Right Cessation
- 1998-05-25 JP JP50057899A patent/JP4002303B2/en not_active Expired - Lifetime
- 1998-05-25 PT PT02019642T patent/PT1273581E/en unknown
- 1998-05-25 AU AU77935/98A patent/AU722839B2/en not_active Expired
- 1998-05-25 DK DK98926005T patent/DK0984957T3/en active
- 1998-05-25 SK SK76-2005A patent/SK285137B6/en not_active IP Right Cessation
- 1998-05-25 ME MEP-180/08A patent/MEP18008A/en unknown
- 1998-05-25 ID IDW991449A patent/ID29306A/en unknown
- 1998-05-25 UA UA99116288A patent/UA60334C2/en unknown
- 1998-05-25 CA CA002521391A patent/CA2521391C/en not_active Expired - Lifetime
- 1998-05-25 RS YUP-609/99A patent/RS50005B/en unknown
- 1998-05-25 SI SI9830761T patent/SI1273581T1/xx unknown
- 1998-05-25 WO PCT/SE1998/000974 patent/WO1998054171A1/en active Application Filing
- 1998-05-25 CZ CZ20041090A patent/CZ297585B6/en not_active IP Right Cessation
- 1998-05-25 SK SK1625-99A patent/SK284837B6/en not_active IP Right Cessation
- 1998-05-25 TR TR1999/02934T patent/TR199902934T2/en unknown
- 1998-05-25 EP EP02019642A patent/EP1273581B1/en not_active Expired - Lifetime
- 1998-05-25 EE EEP199900550A patent/EE03875B1/en active Protection Beyond IP Right Term
- 1998-05-25 SI SI9830424T patent/SI0984957T1/en unknown
- 1998-05-25 AT AT02019642T patent/ATE291574T1/en active
- 1998-05-25 DK DK02019642T patent/DK1273581T3/en active
- 1998-05-25 HU HU0001849A patent/HU225987B1/en active Protection Beyond IP Right Term
- 1998-05-25 ES ES98926005.4T patent/ES2195345T7/en active Active
- 1998-05-25 CN CNB98805521XA patent/CN1161351C/en not_active Expired - Lifetime
- 1998-05-25 KR KR10-2005-7006896A patent/KR100527804B1/en not_active IP Right Cessation
- 1998-05-25 PL PL98337180A patent/PL193546B1/en unknown
- 1998-05-25 CA CA002290963A patent/CA2290963C/en not_active Expired - Lifetime
- 1998-05-25 ME MEP-2008-249A patent/ME00198B/en unknown
- 1998-05-25 RU RU99128072/04A patent/RU2184115C2/en active Protection Beyond IP Right Term
- 1998-05-25 DE DE69814069.9T patent/DE69814069T3/en not_active Expired - Lifetime
- 1998-05-25 ES ES02019642T patent/ES2236407T3/en not_active Expired - Lifetime
- 1998-05-25 AT AT98926005T patent/ATE239011T1/en active
- 1998-05-25 DE DE69829511T patent/DE69829511T2/en not_active Expired - Lifetime
- 1998-05-25 KR KR1019997011106A patent/KR100540720B1/en not_active IP Right Cessation
- 1998-05-25 RS RSP-2007/0459A patent/RS50067B/en unknown
- 1998-05-27 EG EG58098A patent/EG24291A/en active
- 1998-05-29 TN TNTNSN98074A patent/TNSN98074A1/en unknown
- 1998-05-29 MY MYPI98002399A patent/MY120745A/en unknown
- 1998-05-29 MY MYPI20032997A patent/MY127793A/en unknown
- 1998-07-12 SA SA98190280A patent/SA98190280B1/en unknown
- 1998-07-12 SA SA5260296A patent/SA05260296B1/en unknown
-
1999
- 1999-11-25 IS IS5272A patent/IS2142B/en unknown
- 1999-11-29 NO NO19995852A patent/NO317518B1/en not_active IP Right Cessation
-
2000
- 2000-08-17 HK HK03103300A patent/HK1051681A1/en not_active IP Right Cessation
- 2000-08-17 HK HK00105176A patent/HK1025962A1/en not_active IP Right Cessation
-
2002
- 2002-02-14 US US10/076,711 patent/US6677455B2/en not_active Expired - Lifetime
-
2003
- 2003-09-25 US US10/672,936 patent/US7411070B2/en not_active Expired - Fee Related
-
2006
- 2006-03-22 IS IS8368A patent/IS2774B/en unknown
-
2007
- 2007-02-20 AR ARP070100714A patent/AR059589A2/en active IP Right Grant
- 2007-03-16 JP JP2007068061A patent/JP2007161734A/en active Pending
- 2007-09-11 US US11/853,323 patent/US7745466B2/en not_active Expired - Fee Related
-
2010
- 2010-05-21 US US12/784,881 patent/US8076361B2/en not_active Expired - Fee Related
-
2011
- 2011-06-07 NO NO2011010C patent/NO2011010I1/en not_active Application Discontinuation
- 2011-09-19 LU LU91871C patent/LU91871I2/en unknown
- 2011-11-17 US US13/298,373 patent/US8466175B2/en not_active Expired - Fee Related
-
2012
- 2012-03-26 DE DE201212000017 patent/DE122012000017I1/en active Pending
- 2012-06-05 NO NO2012011C patent/NO2012011I1/en unknown
- 2012-06-06 LU LU92017C patent/LU92017I2/en unknown
- 2012-11-05 CY CY2012029C patent/CY2012029I1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2290963C (en) | S-omeprazole magnesium trihydrate | |
| EP1149090A1 (en) | Potassium salt of ($i(s))-omeprazole | |
| US6747155B2 (en) | Process | |
| MXPA99010945A (en) | Novel form of s | |
| CZ296154B6 (en) | Magnesium salt of S-omeprazole trihydrate, process for its preparation and pharmaceutical composition in which the trihydrate is comprised | |
| MXPA01007516A (en) | Potassium salt of (s |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20180525 |